Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported)
November 30,
2018
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
10524 Moss Park Rd., Ste. 204-357
|
|
|
Orlando, FL
|
32832
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 1.01 Entry into a Definitive Material
Agreement.
On November 30, 2018, the Company entered into a Third Amendment to
Forbearance Agreement with GPB DEBT HOLDING II, LLC
(“Lender”), whereby the Lender agreed to forbear its
exercise of registration rights pursuant to Section 4.9 of
the Securities Purchase Agreement dated September 26, 2017
(“SPA”), until January 31,
2019.
Item 5.02 Departure of Directors or Principal
Officers, Election of Directors, Appointment of Principal
Officers.
On November 30, 2018, the Board of Directors (the
“Board”) of MEDITE Cancer Diagnostics, Inc. (the
“Company”) accepted the resignation of Stephen Von Rump
as Chief Strategy Officer of the Company, effective
immediately.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits
|
Exhibit No.
|
Description
|
|
Form of
Third Amendment to Forbearance Agreement
|
|
|
Resignation Letter
of Stephen Von Rump
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
December 6, 2018
|
By:
|
/s/ Elmar A. Dave
|
|
|
|
Elmar
A. Dave
|
|
|
|
Chief
Executive Officer
|
|
|